FDA Regulatory Monday, October 19, 2026 +0.20 Positive

FDA approves therapy for rectal cancer

Accelerated approval of dostarlimab-gxly (Jemperli) allows some patients with locally advanced rectal cancer to avoid chemotherapy and surgery.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed